J&J, AbbVie swell Imbruvica patient pool with FDA nod in CLL

AbbVie ($ABBV) has said it expects nearly a third of Imbruvica's future growth to come from moving into earlier lines of therapy in the drug's approved indications. And Friday, the therapy did just that, snagging a first-line go-ahead from the FDA in patients with chronic lymphocytic leukemia (CLL). More from FiercePharma

Read more on